FAKTOR-OPTIONSSCHEIN - UNITED THERAPEUTICS Share Price

Certificat

DE000MG345D2

Market Closed - Börse Stuttgart 20:20:08 31/05/2024 BST
4.99 EUR -2.54% Intraday chart for FAKTOR-OPTIONSSCHEIN - UNITED THERAPEUTICS
Current month-51.32%
1 month-51.32%
Date Price Change
31/05/24 4.99 -2.54%
30/05/24 5.12 -3.76%
29/05/24 5.32 +0.95%
28/05/24 5.27 +11.89%
27/05/24 4.71 -6.36%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 08:20 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
Issuer Morgan Stanley
WKN MG345D
ISINDE000MG345D2
Date issued 26/04/2024
Strike 338.1 $
Maturity Unlimited
Parity 12.18 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.41
Lowest since issue 4.47
Spread 0.06
Spread %1.24%

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
275.1 USD
Average target price
294.2 USD
Spread / Average Target
+6.92%
Consensus